Published in Cancer Weekly, November 25th, 2003
But many researchers complain that progress is being slowed by commerce. That's because E.I. duPont de Nemours and Co. lays broad intellectual property claims to drug discoveries made with just about any animal genetically engineered to be prone to just about any cancer.
duPont and Harvard claim the terms are typical of such arrangements between industry and academia and aren't particularly onerous. But many researchers and other university patent officials allege that DuPont...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.